13 results
Keyword panitumumab Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Vectibix
panitumumab, Colorectal Neoplasms
Date of authorisation: 03/12/2007, Revision: 30, Authorisedauthorisation for Vectibix (panitumumab) Outcome of re-examination … contains the active substance panitumumab. Vectibix is used to treat … authorisation for Vectibix (panitumumab) EMA/CHMP/486351/2011 … -
List item
Human medicine European public assessment report (EPAR): Portrazza
necitumumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 15/02/2016, Additional monitoring, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Erbitux
cetuximab, Head and Neck Neoplasms Colorectal Neoplasms
Date of authorisation: 29/06/2004, Revision: 25, Authorised -
List item
Human medicine European public assessment report (EPAR): Lonsurf
trifluridine / tipiracil, Colorectal Neoplasms
Date of authorisation: 25/04/2016, Additional monitoring, Revision: 2, Authorisedwild type tumours received panitumumab or cetuximab. The 2 treatment … -
List item
Human medicine European public assessment report (EPAR): Stivarga
regorafenib, Colorectal Neoplasms
Date of authorisation: 26/08/2013, Revision: 14, Authorised -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma Hodgkin Disease Carcinoma, Renal Cell Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015, Additional monitoring, Revision: 21, Authorised -
List item
Human medicine European public assessment report (EPAR): Zaltrap
aflibercept, Colorectal Neoplasms
Date of authorisation: 01/02/2013, Revision: 7, Authorised -
List item
Human medicine European public assessment report (EPAR): Fanaptum
iloperidone, Schizophrenia
Date of refusal: 15/01/2018, Refused -
List item
Human medicine European public assessment report (EPAR): Hemlibra
emicizumab, Hemophilia A
Date of authorisation: 23/02/2018, Additional monitoring, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech
human IgG1 monoclonal antibody specific for human interleukin-1 alpha, Colorectal Neoplasms
Date of refusal: 14/09/2017, Refused -
List item
Human medicine European public assessment report (EPAR): Tyverb
lapatinib, Breast Neoplasms
Date of authorisation: 10/06/2008, Revision: 28, Authorised -
List item
Human medicine European public assessment report (EPAR): Cyramza
ramucirumab, Stomach Neoplasms
Date of authorisation: 19/12/2014, Additional monitoring, Revision: 7, Authorised -
List item
Human medicine European public assessment report (EPAR): Avastin
bevacizumab, Carcinoma, Non-Small-Cell Lung Breast Neoplasms Ovarian Neoplasms Colorectal Neoplasms Carcinoma, Renal Cell
Date of authorisation: 12/01/2005, Revision: 50, Authorised